FIRST REPORT OF COLOMBIAN REGISTRY FOR HEREDITARY ANGIOEDEMA
MARIA
M.
OLIVARES1*,
Rosa
Farfan2,
Jorge
Sanchez2, 3, 4, 5,
Maria
C.
Ortega-Lopez6, 7,
Eduardo
J.
De Zubiria8,
Jairo
A.
Rodriguez9,
CARLOS
E.
OLMOS10,
CATALINA
GOMEZ10,
Jorge
Rabal11,
Alejandro
Carreno12,
Alejandro
Echenique12,
Susana
Diez2, 3, 5 and
Mauricio
Sarrazola13
-
1
Clinica Medellin Poblado, Colombia
-
2
Universidad de Antioquia, Colombia
-
3
Group of clinical and experimental Allergy (GACE), University of Antioquia, Medellín, Colombia, Colombia
-
4
Foundation for the Develoment of Medical and Biological Science (FUNDEMEB), Colombia
-
5
IPS Universitaria Universidad de Antioquia, Medellin, Colombia, Colombia
-
6
Hospital Militar Central, Bogota, Colombia, Colombia
-
7
Fundacion Universitaria de Ciencias de la Salud, Bogota, Colombia, Colombia
-
8
Centro de Alergia e inmunología, Colombia
-
9
Universidad Surcolombiana, Colombia
-
10
CAYRE IPS- Unidad de Alergias e Inmunología, Colombia
-
11
Organizacion Clínica General del norte, Colombia
-
12
Centro de alergología Alejandro Carreño SAS, Colombia
-
13
Clinica San José, Colombia
RATIONALE: Hereditary angioedema (HAE), is a syndrome characterized by skin or mucosal angioedema that is caused by deficiency or dysfunction of C1 esterase inhibitor and is inherited in an autosomal dominant manner. We present the frequency reported in Colombia of patients diagnosed with HAE, as a preliminary result of an ongoing project which will permit the first Colombian record of this disease.
METHODS: A questionnaire on the diagnosis, treatment and current control of patients with HAE, was completed by allergists and immunologists (n = 13) of Colombia.
RESULTS: 33 patients with confirmed diagnosis of HAE were reported. The average age of onset of symptoms was 15 years old, with an average age at diagnosis of 31 years. 6% of the patients required tracheostomy, and 12% have required intubation sometime in their life. 87.8% with positive family history for the disease. 54.5% with family history of death by respiratory obstruction. 48% of patients are currently in maintenance treatment: 44% with danazol, tranexamic acid 4%; 9% of patients Icatiban used for handling the crisis. 85% of patients have had episodes of edema in the last year.
CONCLUSIONS: Although the number of patients is low, our data show that the diagnosis of the disease in our country is late with a high morbidity and mortality in affected families. In Colombia, we need to know the real frequency of patients affected to do adequate health politics.
References
WAO Guideline for the management of hereditary angioedema.WAO Journal 2012;5:182-199
Current state of hereditary angioedema management: A patient survey.Allergy Asthma Proc. 2015 May;36(3):213-7
Keywords:
Hereditary angioedema (HAE),
Registry,
C1 Inhibitor,
Colombia,
diagnosis
Conference:
IMMUNOCOLOMBIA2015 - 11th Congress of the Latin American Association of Immunology - 10o. Congreso de la Asociación Colombiana de Alergia, Asma e Inmunología, Medellin, Colombia, 13 Oct - 16 Oct, 2015.
Presentation Type:
Poster Presentation
Topic:
Immunodeficiencies
Citation:
OLIVARES
MM,
Farfan
R,
Sanchez
J,
Ortega-Lopez
MC,
De Zubiria
EJ,
Rodriguez
JA,
OLMOS
CE,
GOMEZ
C,
Rabal
J,
Carreno
A,
Echenique
A,
Diez
S and
Sarrazola
M
(2015). FIRST REPORT OF COLOMBIAN REGISTRY FOR HEREDITARY ANGIOEDEMA.
Front. Immunol.
Conference Abstract:
IMMUNOCOLOMBIA2015 - 11th Congress of the Latin American Association of Immunology - 10o. Congreso de la Asociación Colombiana de Alergia, Asma e Inmunología.
doi: 10.3389/conf.fimmu.2015.05.00132
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
02 Jun 2015;
Published Online:
14 Sep 2015.
*
Correspondence:
MD. MARIA M OLIVARES, Clinica Medellin Poblado, medellín, Colombia, consultorioalergias@gmail.com